Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

Leuk Res. 2011 Jan;35(1):3-7. doi: 10.1016/j.leukres.2010.06.018. Epub 2010 Jul 31.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Transplantation
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / pathology*
  • Leukemia, Promyelocytic, Acute / surgery
  • Monitoring, Physiologic / methods*
  • Neoplasm, Residual*

Substances

  • Antineoplastic Agents